

Special Issue

SARS-CoV-2, COVID-19 Pathologies, Long COVID, and Anti-COVID Vaccines

Message from the Guest Editor

This Special Issue of the international scientific journal *Viruses* concerns the SARS-CoV-2 virus, the pathologies of COVID-19, and long COVID, as well as anti-COVID vaccines and their potential harmful effects on the human body (in particular, mRNA vaccines). All aspects are covered in this Special Issue, from the mode of action of the virus or the Spike protein, to the adverse effects concerning neurodegeneration, cardiovascular and gastrointestinal disorders, autoimmunity, and cancers. The dysregulation of the renin–angiotensin system and the overactivation of the AT1R receptor by excess angiotensin-2, at the origin of COVID-19 pathologies or long COVID, are included in this Special Issue. Potential drug treatments can be discussed depending on the case.

Guest Editor

Dr. Jean-Marc Sabatier

Faculté des Sciences Médicales et Paramédicales, Institute of Neurophysiopathology (INP), Aix-Marseille University, 27, Bd Jean Moulin, 13005 Marseille, France

Deadline for manuscript submissions

31 December 2025



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/239607

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/

[viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).